Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment

International Journal of Urology

Volumn 15, Issue 1, 2008, Pages 19-26

  Uemura, Hiroji ^a   Ishiguro, Hitoshi ^a   Kubota, Yoshinobu ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II; Angiotensin II receptor; Angiotensin II receptor blocker; Prostate cancer; Renin angiotensin system

Indexed keywords

ANDROGEN RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR; CANDESARTAN; CATHEPSIN G; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ELASTASE; ENDOTHELIN RECEPTOR; EPIDERMAL GROWTH FACTOR; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LOSARTAN; LOSARTAN POTASSIUM; LYSOPHOSPHATIDIC ACID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; STAT3 PROTEIN; TELMISARTAN; TISSUE PLASMINOGEN ACTIVATOR; TONIN; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CYTOKINES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PPAR GAMMA; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RENIN-ANGIOTENSIN SYSTEM; STROMAL CELLS; TREATMENT OUTCOME;

EID: 37849053338     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01937.x     Document Type: Review

References (103)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 2002 52 : 23 47.
2. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int. J. Urol. 2005 12 : 46 61.
3. Imaizumi Y. Longitudinal gompertzian analysis of mortality from prostate cancer in Japan, 1955-1996. Cancer Detect. Prev. 2000 24 : 473 84.
4. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 1972 22 : 232 40.
5. Heffelfinger SC. The renin angiotensin system in the regulation of angiogenesis. Curr. Pharm. Des. 2007 13 : 1215 29.
6. Lever AF, Hole DJ, Gillis CR et al. Do inhibitors of angiotensin-I- converting enzyme protect against risk of cancer? Lancet 1998 352 : 179 84.
7. Ronquist G, Rodriguez LA, Ruigomez A et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004 58 : 50 6.
8. Uemura H, Ishiguro H, Nakaigawa N et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol. Cancer Ther. 2003 2 : 1139 47.
9. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004 61 : 332 53.
10. Miyoshi Y, Uemura H, Fujinami K et al. Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 2000 43 : 225 32.
11. Linja MJ, Savinainen KJ, Saramaki OR et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001 61 : 3550 5.
12. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995 332 : 1393 8.
13. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: An overview. Endocr. Rev. 2002 23 : 175 200.
14. Miyoshi Y, Ishiguro H, Uemura H et al. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003 56 : 280 6.
15. Di Lorenzo G, Tortora G, D'Armiento FP et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 2002 8 : 3438 44.
16. Morris GL, Dodd JG. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J. Urol. 1990 143 : 1272 4.
17. Scher HI, Sarkis A, Reuter V et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin. Cancer Res. 1995 1 : 545 50.
18. Voronov E, Shouval DS, Krelin Y et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad. Sci. USA 2003 100 : 2645 50.
19. Kuniyasu H, Troncoso P, Johnston D et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin. Cancer Res. 2000 6 : 2295 308.
20. Wu JD, Haugk K, Woodke L et al. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell. Biochem. 2006 99 : 392 401.
21. Hobisch A, Eder IE, Putz T et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998 58 : 4640 5.
22. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 2000 60 : 2132 5.
23. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 2002 277 : 7076 85.
24. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin. Cancer Res. 2001 7 : 1773 81.
25. Kim SJ, Uehara H, Karashima T et al. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001 3 : 33 42.
26. Inoue K, Slaton JW, Eve BY et al. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 2000 6 : 2104 19.
27. Wise GJ, Marella VK, Talluri G, Shirazian D. Cytokine variations in patients with hormone treated prostate cancer. J. Urol. 2000 164 : 722 5.
28. Kambayashi Y, Bardhan S, Takahashi K et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J. Biol. Chem. 1993 268 : 24 43 6.
29. Mukoyama M, Nakajima M, Horiuchi M et al. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 1993 268 : 24 39 42.
30. Fabiani ME, Johnston CI. Spectrum of use for the angiotensin-receptor blocking drugs. Curr. Hypertens. Rep. 1999 1 : 394 401.
31. Chung O, Kuhl H, Stoll M, Unger T. Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int. Suppl. 1998 67 : S95 9.
32. Dzau VJ. Cell biology and genetics of angiotensin in cardiovascular disease. J. Hypertens. Suppl. 1994 12 : S3 10.
33. Huckle WR, Earp HS. Regulation of cell proliferation and growth by angiotensin II. Prog. Growth Factor Res. 1994 5 : 177 94.
34. Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J. Am. Coll. Cardiol. 1996 28 : 803 12.
35. Bader M, Peters J, Baltatu O et al. Tissue renin-angiotensin systems: New insights from experimental animal models in hypertension research. J. Mol. Med. 2001 79 : 76 102.
36. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000 35 : 1270 7.
37. Davisson RL. Physiological genomic analysis of the brain renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003 285 : R498 511.
38. Mulrow PJ. The intrarenal renin-angiotensin system. Curr. Opin. Nephrol. Hypertens. 1993 2 : 41 4.
39. Chappell MC, Diz DI, Gallagher PE. The renin-angiotensin system and the exocrine pancreas. JOP 2001 2 : 33 9.
40. Speth RC, Daubert DL, Grove KL. Angiotensin II: A reproductive hormone too? Regul. Pept. 1999 79 : 25 40.
41. Uemura H, Hasumi H, Ishiguro H et al. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006 66 : 822 30.
42. Nielsen AH, Schauser KH, Poulsen K. Current topic: The uteroplacental renin-angiotensin system. Placenta 2000 21 : 468 77.
43. Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. J. Biol. Chem. 1982 257 : 15 42 6.
44. Schiller PW, Demassieux S, Boucher R. Substrate specificity of tonin from rat submaxillary gland. Circ. Res. 1976 39 : 629 32.
45. Baltatu O, Nishimura H, Hoffmann S et al. High levels of human chymase expression in the pineal and pituitary glands. Brain Res. 1997 752 : 269 78.
46. Tahmasebi M, Puddefoot JR, Inwang ER et al. Transcription of the prorenin gene in normal and diseased breast. Eur. J. Cancer 1998 34 : 1777 82.
47. Marsigliante S, Resta L, Muscella A et al. AT1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma. Cancer Lett. 1996 110 : 19 27.
48. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001 495 : 197 200.
49. Ino K, Uehara C, Kikkawa F et al. Enhancement of aminopeptidase A expression during angiotensin II-induced choriocarcinoma cell proliferation through AT1 receptor involving protein kinase C- and mitogen-activated protein kinase-dependent signaling pathway. J. Clin. Endocrinol. Metab. 2003 88 : 3973 82.
50. Tsuzuki S, Ichiki T, Nakakubo H et al. Molecular cloning and expression of the gene encoding human angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 1994 200 : 1449 54.
51. Wolf G, Harendza S, Schroeder R et al. Angiotensin II's antiproliferative effects mediated through AT2-receptors depend on down-regulation of SM-20. Lab. Invest. 2002 82 : 1305 17.
52. Chen L, Re RN, Prakash O, Mondal D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc. Soc. Exp. Biol. Med. 1991 196 : 280 3.
53. Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc. Soc. Exp. Biol. Med. 1995 210 : 221 6.
54. Hii SI, Nicol DL, Gotley DC et al. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br. J. Cancer 1998 77 : 880 3.
55. Volpert OV, Ward WF, Lingen MW et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 1996 98 : 671 9.
56. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001 103 : 904 12.
57. Dina R, Jafari M. Angiotensin II-receptor antagonists: An overview. Am. J. Health Syst. Pharm. 2000 57 : 1231 41.
58. Chung O, Csikos T, Unger T. Angiotensin II receptor pharmacology and AT1-receptor blockers. J. Hum. Hypertens. 1999 13 : S11 20 discussion S33 14.
59. Gohlke P, Linz W, Scholkens BA et al. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996 28 : 397 402.
60. Schieffer B, Wirger A, Meybrunn M et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994 89 : 2273 82.
61. Remuzzi A, Malanchini B, Battaglia C et al. Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp. Nephrol. 1996 4 : 19 25.
62. Asakura M, Kitakaze M, Takashima S et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy. Nat. Med. 2002 8 : 35 40.
63. Deshayes F, Nahmias C. Angiotensin receptors: A new role in cancer? Trends Endocrinol. Metab. 2005 16 : 293 9.
64. Lee SO, Lou W, Johnson CS et al. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate 2004 60 : 178 86.
65. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000 42 : 150 60.
66. Suzuki Y, Ruiz-Ortega M, Lorenzo O et al. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 2003 35 : 881 900.
67. Uemura H, Ishiguro H, Nagashima Y et al. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol. Cancer Ther. 2005 4 : 1699 709.
68. Bok RA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study. Cancer Res. 2001 61 : 2533 6.
69. Drachenberg DE, Elgamal AA, Rowbotham R et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999 41 : 127 33.
70. Small EJ, Reese DM, Um B et al. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 1999 5 : 1738 44.
71. Lee LF, Louie MC, Desai SJ et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: Differential effects of tyrosine kinases Src and FAK. Oncogene 2004 23 : 2197 205.
72. Ohta M, Kitadai Y, Tanaka S et al. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int. J. Oncol. 2003 22 : 773 8.
73. Uemura H, Hasumi H, Kawahara T et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int. J. Clin. Oncol. 2005 10 : 405 10.
74. Sano M, Fukuda K, Sato T et al. ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ. Res. 2001 89 : 661 9.
75. Logothetis CJ, Wu KK, Finn LD et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 2001 7 : 1198 203.
76. Arafat HA, Gong Q, Chipitsyna G et al. Antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J. Am. Coll. Surg. 2007 204 : 996 1005 discussion 1005 6.
77. Egami K, Murohara T, Shimada T et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 2003 112 : 67 75.
78. Schupp N, Schmid U, Rutkowski P et al. Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging. Am. J. Physiol. Renal Physiol. 2007 292 : F1427 34.
79. Suganuma T, Ino K, Shibata K et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 2005 11 : 2686 94.
80. Yamagishi T, Uemura H, Nakaigawa N et al. Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer. J. Urol. 2005 173 : 441.
81. Meffert S, Stoll M, Steckelings UM et al. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol. Cell. Endocrinol. 1996 122 : 59 67.
82. Rivera E, Arrieta O, Guevara P et al. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br. J. Cancer 2001 85 : 1396 9.
83. Nakajima M, Hutchinson HG, Fujinaga M et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: Gain-of-function study using gene transfer. Proc. Natl Acad. Sci. USA 1995 92 : 10 63 7.
84. Morrissey JJ, Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am. J. Physiol. 1999 276 : F39 45.
85. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system. J. Hypertens. 2004 22 : 2253 61.
86. Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004 43 : 993 1002.
87. Lehmann JM, Moore LB, Smith-Oliver TA et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995 270 : 12 53 6.
88. Rosen ED, Spiegelman BM. PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 2001 276 : 37 31 4.
89. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 2000 43 : 527 50.
90. Berger J, Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med. 2002 53 : 409 35.
91. Picard F, Auwerx J. PPAR (gamma) and glucose homeostasis. Annu. Rev. Nutr. 2002 22 : 167 97.
92. Walczak R, Tontonoz P. PPARadigms and PPARadoxes: Expanding roles for PPARgamma in the control of lipid metabolism. J. Lipid Res. 2002 43 : 177 86.
93. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007 67 : 924 32.
94. Shappell SB, Gupta RA, Manning S et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001 61 : 497 503.
95. Nwankwo JO, Robbins ME. Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot. Essent. Fatty Acids 2001 64 : 241 5.
96. Rangwala SM, Lazar MA. The dawn of the SPPARMs? Sci. STKE 2002 2002 : PE9.
97. Berger JP, Petro AE, Macnaul KL et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol. Endocrinol. 2003 17 : 662 76.
98. Derosa G, Ragonesi PD, Mugellini A et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: A randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res. 2004 27 : 457 64.
99. Im DS, Heise CE, Harding MA et al. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol. Pharmacol. 2000 57 : 753 9.
100. Nelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1995 1 : 944 9.
101. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000 44 : 77 87.
102. Barki-Harrington L, Daaka Y. Bradykinin induced mitogenesis of androgen independent prostate cancer cells. J. Urol. 2001 165 : 2121 5.
103. Xu LL, Stackhouse BG, Florence K et al. PSGR, a novel prostate- specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res. 2000 60 : 6568 72.